Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes

BACKGROUNDDiabetes mellitus is a global epidemic primarily driven by pancreatic β-cell dysfunction.Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for diabetes, yet their underlying mechanisms remain incompletely understood.The circular RNA ciRS-7 (CDR1as) sponges miR-7, a negative regulator of β-cell function, affecting downstream targets Myrip and Pax6.However, whether MSC treatment is associated with this axis is unknown. AIMTo investigate whether MSC treatment is associated with modulation of the ciRS-7/miR-7/Myrip/Pax6 axis and with changes in β-cell function in diabetes. METHODSIn vitro, in INS-1 β-cells, ciRS-7 was silenced using specific siRNAs or overexpressed via plasmid transfection, followed by co-culture with MSCs.Cell Counting Kit-8 absorbance in the co-culture system, insulin levels in the culture supernatant (enzyme-linked immunosorbent assay), and expression of ciRS-7, miR-7, Myrip, and Pax6 (quantitative reverse transcription PCR/Western blot) were measured.In vivo, type 2 diabetes mellitus rats were treated with human umbilical cord MSCs (hUC-MSCs) or phosphate-buffered saline; blood glucose, intraperitoneal glucose tolerance test, pancreatic histology, β-cell ultrastructure, and molecular changes were evaluated. RESULTSIn vitro, MSC treatment was associated with increased total ciRS-7 in the co-culture system and insulin levels in the culture supernatant in a dose-dependent manner.ciRS-7 knockdown attenuated these MSC-associated effects, while ciRS-7 overexpression 4 / 40 enhanced them, along with reciprocal changes in miR-7, Myrip, and Pax6.In vivo, hUC-MSC treatment improved glycemic control and glucose tolerance and was associated with structural changes consistent with improved islet morphology, as well as upregulation of ciRS-7, Pax6, and Myrip and downregulation of miR-7. CONCLUSIONThese findings link MSC-based therapy to the ciRS-7/miR-7/Myrip/Pax6 axis.MSC treatment was associated with significant improvement in glycemic control and with changes in this axis.

Authors

Institutions

Publication Details

Journal
World Journal of Diabetes
Published
2026-11-16
DOI
https://doi.org/10.4239/wjd.125659
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes

Yi-yao ZHU, Yu Zhao, Chen Liu, Jia-Yu Huang et al.
1 links
World Journal of Diabetes
Pancreatic function and diabetes
article

Association between mesenchymal stem cell treatment and modulation of the ciRS-7/miR-7/Myrip/Pax6 axis in diabetes

Yi-yao ZHU, Yu Zhao, Chen Liu, Jia-Yu Huang, Jing Xue, Dan Wu, Zhen-Lin Tan, Dong-Hui Lu, Yan Liao, Zheng Feng
article en

Abstract

BACKGROUNDDiabetes mellitus is a global epidemic primarily driven by pancreatic β-cell dysfunction.Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for diabetes, yet their underlying mechanisms remain incompletely understood.The circular RNA ciRS-7 (CDR1as) sponges miR-7, a negative regulator of β-cell function, affecting downstream targets Myrip and Pax6.However, whether MSC treatment is associated with this axis is unknown. AIMTo investigate whether MSC treatment is associated with modulation of the ciRS-7/miR-7/Myrip/Pax6 axis and with changes in β-cell function in diabetes. METHODSIn vitro, in INS-1 β-cells, ciRS-7 was silenced using specific siRNAs or overexpressed via plasmid transfection, followed by co-culture with MSCs.Cell Counting Kit-8 absorbance in the co-culture system, insulin levels in the culture supernatant (enzyme-linked immunosorbent assay), and expression of ciRS-7, miR-7, Myrip, and Pax6 (quantitative reverse transcription PCR/Western blot) were measured.In vivo, type 2 diabetes mellitus rats were treated with human umbilical cord MSCs (hUC-MSCs) or phosphate-buffered saline; blood glucose, intraperitoneal glucose tolerance test, pancreatic histology, β-cell ultrastructure, and molecular changes were evaluated. RESULTSIn vitro, MSC treatment was associated with increased total ciRS-7 in the co-culture system and insulin levels in the culture supernatant in a dose-dependent manner.ciRS-7 knockdown attenuated these MSC-associated effects, while ciRS-7 overexpression 4 / 40 enhanced them, along with reciprocal changes in miR-7, Myrip, and Pax6.In vivo, hUC-MSC treatment improved glycemic control and glucose tolerance and was associated with structural changes consistent with improved islet morphology, as well as upregulation of ciRS-7, Pax6, and Myrip and downregulation of miR-7. CONCLUSIONThese findings link MSC-based therapy to the ciRS-7/miR-7/Myrip/Pax6 axis.MSC treatment was associated with significant improvement in glycemic control and with changes in this axis.

World Journal of Diabetes
Guangzhou University of Chinese Medicine (CN), Guangdong Medical College (CN), Shantou University Medical College (CN), Beike Biotechnology (China) (CN), Peking University Shenzhen Hospital (CN), Shenzhen Bao'an District People's Hospital (CN)
Good health and well-being
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon